XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Debt - 2018 Purchase Agreement and Indenture for Scilex and Bridge Loan Agreement - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Jun. 03, 2022
Feb. 16, 2022
Sep. 07, 2018
Oct. 31, 2022
Sep. 30, 2022
Aug. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Jun. 02, 2022
Feb. 15, 2022
Feb. 14, 2022
Oct. 05, 2018
Debt Instrument [Line Items]                                  
Gain (loss) on debt extinguishment               $ 33,433,000     $ 27,701,000 $ (6,695,000)          
Gain (loss) on derivative liabilities               500,000   $ (1,800,000) 5,300,000 100,000          
Proceed received, net of transaction fees                     98,560,000 35,053,000          
B. Riley Commercial Capital, LLC | September Bridge Loan Agreement | September Bridge Loan                                  
Debt Instrument [Line Items]                                  
Short-term borrowings $ 41,600,000         $ 41,600,000   $ 41,600,000     $ 41,600,000            
Interest rate 6.00%         6.00%   6.00%     6.00%            
Debt instrument maturity date Jan. 31, 2023                                
Transaction fees $ 400,000                                
Proceed received, net of transaction fees 41,200,000                                
Advisory fees paid 1,300,000                                
Debt discount 1,700,000                                
Repayment of the Loan         $ 10,000,000.0                        
B. Riley Commercial Capital, LLC | Bridge Loan Agreement | Bridge Loan                                  
Debt Instrument [Line Items]                                  
Gain (loss) on debt extinguishment                     $ (900,000)            
Amount of debt discount and debt issuance included in interest expense                     900,000            
Short-term borrowings     $ 45,000,000.0                            
Debt instrument maturity date     Jun. 16, 2022                            
Scilex Pharmaceuticals, Inc                                  
Debt Instrument [Line Items]                                  
Derivative liabilities 0         $ 0   $ 0     0            
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026                                  
Debt Instrument [Line Items]                                  
Face value of loan       $ 224,000,000.0                 $ 133,998,000        
Proceeds from issuance of senior long-term debt       $ 140,000,000.0                          
Principal amount to be purchased                               $ 20,000,000.0  
Gain (loss) on debt extinguishment               (33,400,000)     28,600,000 (14,000,000.0)          
Derivative liabilities $ 0         0   0     0            
Principal payments           39,700,000 $ 1,700,000       106,000,000.0 44,200,000          
Amount of debt discount and debt issuance included in interest expense               $ 100,000   $ 1,900,000 $ 3,100,000 $ 5,900,000          
Remaining principal amount   $ 41,400,000                              
Redemption price as a percentage of outstanding principal   100.00%                              
Discharge of aggregate principal amount   $ 28,000,000.0                              
Aggregate unrestricted cash equivalents                           $ 5,000,000.0      
Decrease in fair value                 $ 30,400,000                
Increase in carrying value                 30,400,000                
Carrying value                 74,900,000       101,162,000        
Principal amount of the Scilex Notes forgiven           $ 28,000,000.0                      
Debt instrument, gain recognized                 $ 0                
Effective rate, description                     Due to a decrease of $30.4 million in the fair value of the Scilex Notes Derivative caused by the Indenture Amendment, the carrying value of the Scilex Notes was increased by $30.4 million, totaling $74.9 million at June 30, 2022.            
Senior Notes | Scilex Pharmaceuticals, Inc | Senior Secured Notes, Due 2026 | ZTlido                                  
Debt Instrument [Line Items]                                  
Face value of loan                         $ 28,000,000.0        
Additional principal payments, sales threshold                         95.00%        
Increase to aggregate principal amount                             $ 28,000,000.0    
Expected additional principal payments, sales threshold                     80.00%            
Senior Notes | Scilex Pharmaceuticals, Inc | Minimum | Senior Secured Notes, Due 2026                                  
Debt Instrument [Line Items]                                  
Debt instrument increased to face amount                                 $ 25,000,000.0
Senior Notes | Scilex Pharmaceuticals, Inc | Maximum | Senior Secured Notes, Due 2026                                  
Debt Instrument [Line Items]                                  
Debt instrument increased to face amount                                 $ 50,000,000.0
Subordinated Loan | Scilex Pharmaceuticals, Inc | Net Sales from Issue Date to December 31, 2021 Less than Specified Threshold | ZTlido                                  
Debt Instrument [Line Items]                                  
Face value of loan                               $ 35,000,000.0